Takeda To Help Develop Lundbeck's First-In-Class Mood Disorder Candidates In Japan, U.S.
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical has taken a step to round out its pipeline by adding mood and anxiety disorder candidates under an agreement with Danish pharma H. Lundbeck